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ABSTRACT
Haematopoietic stem cell transplantation has become a well-
established therapy for many severe congenital or acquired 
disorders of the haematopoietic system.  Contrarily to most 
European countries, there is no Registry of Haematopoietic 
Stem Cell Transplantation in Belgium.  A retrospective study 
revealed that results of Belgian paediatric transplantations 
were similar to results of the European for Blood Marrow 
Transplantation (EBMT) group.
In the field of Haematopoietic Stem Cell Transplantation, 
an accreditation of transplant centres should been required 
to be allowed to perform transplantations.  The Joint 
Accreditation Committee-ISCT & EBMT (JACIE) is a non-profit 
body established in 1998 for the purposes of assessment 
and accreditation in the field of haematopoietic stem cell 
transplantation 
In Belgium, it is likely that in the future the centre density (the 
highest of Europe) will decline.  On request of JACIE, a centre 
should be accredited for allogeneic transplantation only if it 
performs > 10 allografts per year.  For the pediatric activity, an 
average of about 20-25 allografts per year were performed for 
children (<18 years) in the last past five years.
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FOR CHILDREN IN BELGIUM 
Introduction
Haematopoietic stem cell transplantation (SCT) has become a well-established therapy for many severe congenital or acquired disorders of the 
haematopoietic system. Contrarily to most European 
countries, there is no Registry of Haematopoietic Stem 
Cell Transplantation in Belgium.  A retrospective study (2) 
revealed that results of Belgian paediatric transplantations 
were similar to results of the European for Blood Marrow 
Transplantation (EBMT) group (www.ebmt.org).
EBMT is a non-profit organisation established in 1974 in 
order to allow scientists and physicians involved in clinical 
bone marrow transplantation to share their experience and 
develop cooperative studies.  In 1996, the “EBMT Working 
Party Paediatric Diseases” was created.
Figure 1: Haematopoietic Stem Cell Transplantation rate in Europe in 1990 (A) and in 2000 (B). (4)
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Figure 2: Number of transplants (autografts and allografts) per year  
in Europe from 1990 to 2000. (3)
Activity in Europe: EBMT
In 2002, 586 centres in 39 European countries carried 
out 20,207 transplantations (30% allogenic and 70% 
autologous).  The highest team density in Europe (defined 
by the number of centres per 10 millions inhabitants) is 
found in Belgium (18.4 centres for 10 millions inhabitants). 
The lowest density centre is found in England (8.8) and in 
Holland (8.7).
The source of stem cells varied in time.  In 1990, bone 
marrow cells were the principal source of cells.  Ten years 
later, 80% of grafts originated from peripheral blood stem 
cells.  The first cord blood transplantation was performed 
in 1989.  In 2002, 162 cord blood transplantations were 
performed in Europe. The transplantation rate (defined by 
the number of transplants by 10 millions inhabitants) is 
variable from one country to another (Figure 1).  In Belgium, 
it is high (more than 400 transplants by 10 million inhabitants) 
(4) Figure 2 shows the evolution of transplantation in Europe 
from 1990 to 2000.
Articles originaux à thème
Originele Artikels met thema
Tijdschrift van de Belgische Kinderarts • Vol. 1  - 2007 - Nr.1     46
Haematopoietic stem cell 
transplantation in Belgium
The Marrow Donor Program Belgium was created to recruit 
and facilitate transplantations from Belgian and foreign 
donors.  
Today, a patient search for a 
matching marrow or blood cell 
donor can include more than 6 
millions volunteer donors on the 
National Marrow Donor Registry 
(NMDP; http://www.marrow.
org/ABOUT/Cord_Blood/NMDP_
Center_for_Cord_Blood) in the 
United States, the largest donor 
registry in the world. An additional 
4 millions volunteer donors are 
available in other international 
registries. The Registry Networks 
extend worldwide, with donor 
centres, transplant centres and 
registries having cooperative 
agreements.
Cord blood transplantation has 
the potential to significantly 
increase the opportunity for 
transplant for seriously ill patients, 
especially those from ethnically 
diverse communities. Through 
the international network of cord 
blood banks Netcord, more than 150,000 cord blood units 
are listed in the world. 
The «Belgium Cord Blood Bank» was created in 1993. 
Three cord blood banks were created with the funds of “Le 
Fonds National de Recherche Scientifique” (FNRS) and the 
yearly “Télévie” fund raising project.  They are based at the 
Catholic University of Louvain (UCL), the Free University 
of Brussels (ULB) and the University of Liege (ULg). More 
than 5.000 cord blood units are stored in these banks. 
The number of units used for transplantation increases 
constantly (Figure 3).
Other cord blood banks have also been created at the 
Catholic University of Leuven (KUL) and the University of 
Ghent (RUG).
Figure 3 : Number of cord blood units from the Belgian cord Blood Bank used for 
transplantation from 1996 to 2006 (www.chuliege.be : Laboratory of Cellular and Gene 
Therapy-Cord Blood Bank)
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Paediatric activity 
in Europe : EBMT
Paediatric transplants (children < 18 years) 
represent 18 % of all the transplant activity 
during the period from 1970 to 2003 (1). 
Paediatric transplants were performed in 
395 centres in 28 European countries. 
Only 25% of the centres performed 
exclusively paediatric transplants.  But in 
the last years, the proportion of centres 
treating only children increased, with a 
figure of 40% (n=89) in 2002.  From 1970 
to 2000, the vast majority of paediatric 
transplantations were performed in 
5 countries: France (n=7,076), Italy 
(n=5,429), UK (n=3,622), Germany 
(n=2,188) and Spain (n=2,034).  Belgium 
registered 513 paediatric transplants 
(allografts: 315, autografts: 198). 
Contrary to adults, allogeneic transplants 
represent the vast majority of paediatric 
activity.  The more frequent indications 
for paediatric transplantation were acute 
lymphoblastic leukaemia (ALL) (n=8,340, 
76 % allogeneic), solid tumour (n=7,956, 
97 % autologous), non malignant disease 
(n= 7,424, 98 % allogeneic), acute 
myeloid leukaemia (AML)  (n=4,788, 67 % 
allogeneic), lymphoma (n=2,480 , 80 % 
autologous), chronic myeloid leukaemia 
(CML) (n=1,183, 96% allogeneic) and 
myelodysplastic syndrome (MDS) 
(n=697, 96 % allogeneic).
Since 1996, the number of children 
treated with an allograft for ALL, AML or 
CML is stable. But more allografts are 
performed for lymphoma and MDS.  The 
number of autografts for ALL and AML 
has dropped considerably.  In contrast, 
the number of autografts for solid tumour 
is increasing.
In 2005, the EBMT defined the indications 
for haematopoietic stem cell transplants 
based on the disease and the donor (7). 
(Table 1)
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Immunodeficiency S S NA














Hodgkin’s disease  
CR1







Thalassemia major S CO NA
Sickle cell disease S CO NA
Severe  aplastic 
anemia
S S NA
































Auto-immune disease NR NR CO
CR1: first complete remission, CR2: second complete remission, CR3: third 
complete remission, S : standard of care, CO : clinical option, can be carried out 
after careful assessment of risks and benefits, D : developmental, further trials are 
needed, NR: non recommended indications, NA : not applicable.
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Paediatric transplantation 
activity in Belgium 
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Figure 4: Number of paediatric transplants in Belgium between 1988 and 2003
Between 1970 and 2000, 513 children (<18 years) were registered at the 
EBMT for Belgium. This included 315 allotransplants and 198 autotransplants. 
However, these numbers are not complete... 
A retrospective study was thus conducted on the 595 paediatric transplants 
performed between 1988 and 1999 in Belgium.  Paediatric transplants in 
Belgium represented 13.5 % of the Belgian activity (in the EBMT paediatric 
activity is 18%).  The number of paediatric transplants per year is relatively 
stable (Figure 4).
A difference was noted in the proportion of paediatric centres in the EBMT 
(38.5%) and in Belgium (12.5%).  Among the 24 Belgian transplant centres, 
paediatric transplants were performed in 6 centres.  Two centres performed 
only paediatric transplants (UCL and HUDERF) and six centres performed only 
autografts.  Contrary to the adults, the majority of transplantations were allogeneic 
(64%), with 27% performed with an unrelated donor, a proportion similar that 
reported by the EBMT (60% allogeneic).  Indications for transplantation in 
children in Belgium are the same as in the EBMT, except that more transplants 
are performed for sickle cell anemia and fewer autografts for solid tumour in 
Belgium. The majority of paediatric transplants are performed for leukaemia 
and myelodysplasic syndromes (46% of all paediatric transplants in Belgium).  
The Event-Free Survival (EFS) for the whole group of paediatric transplants 
is 57% at 1 year and 48% at 5 years. There is no statistically significant 
difference between results of allografts and autografts but they are performed 
for different indications.  In general, these results are comparable with the 
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results from the EBMT and the IBMTR (International Bone 
Marrow Transplant Registry) (htpp://www.ibmtr.org).  Like 
in other registries, there is no difference between allografts 
performed with bone marrow or peripheral blood stem 
cells (PBSC), but more chronic graft-versus-host disease 
(CGVHD) is seen when the graft is from PBSC. (9)  During 
the period covered by our retrospective study, results of 
unrelated donor transplants were worse in Belgium.  But 
this cohort is limited in number and closed in 1999.  In 
the last 5 years, progress has been made in unrelated 
transplants, with results becoming comparable with 
those of familial transplantation. (5,6)  Indeed the year of 
transplantation has a significant impact on the results for 
unrelated transplants. (8)
Contrarily to other European countries, in Belgium, there 
is not yet a “Pediatric Oncology Program”. In the field of 
Haematopoietic Stem Cell Transplantation, an accreditation 
of transplant centres should been required to be allowed to 
perform transplantations.
The Joint Accreditation Committee-ISCT & EBMT (JACIE) 
is a non-profit body established in 1998 for the purposes of 
assessment and accreditation in the field of haematopoietic 
stem cell transplantation. The Committee was founded by 
the European Group for Blood and Marrow Transplantation 
(EBMT) and the International Society for Cellular Therapy 
(http://www.celltherapysociety.org), the two leading 
scientific organisations involved with SCT transplantation 
in Europe.  JACIE’s primary aim is to promote high quality 
patient care and laboratory performance in haematopoietic 
stem cell collection, processing and transplantation 
centres through an internationally recognised system of 
accreditation.  JACIE (http://www.jacie.org), in collaboration 
with the Foundation for the Accreditation of Cellular Therapy 
(http://www.factwebsite.org) in the USA, has established 
standards in SC, encourages health institutions and facilities 
performing SCT to voluntarily meet these standards, and 
conducts inspections and acknowledges compliance with 
the standards by issuing Certificates of Accreditation.
In Belgium, it is likely that in the future the centre density 
(the highest of Europe) will decline.  On request of JACIE, a 
centre should be accredited for allogeneic transplantation 
only if it performs > 10 allografts per year.  For the pediatric 
activity, an average of about 20-25 allografts per year were 
performed for children (<18 years) in the last past five 
years.
Currently, funds for a Belgian Registry of Haematopoietic 
Stem Cell Transplantation under the umbrella of the Belgian 
Haematological Society (BHS) are in discussion at the 
Public Health levels.
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